EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSMAMG00000005282
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSMAMG00000010580
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha-Like

Ensembl ID : ENSMAMG00000004666
Gene Symbol: LOC113143883
2 Cross references
253 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit A

Ensembl ID : ENSMAMG00000011361
Gene Symbol: SCN8AA
2 Cross references
215 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit B

Ensembl ID : ENSMAMG00000002838
Gene Symbol: SCN8AB
2 Cross references
216 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSMAMG00000017042
Gene Symbol: SCN10A
3 Cross references
248 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSMAMG00000021276
Gene Symbol: LOC113127495
3 Cross references
181 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSMAMG00000021265
Gene Symbol: LOC113127499
2 Cross references
220 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1-Like

Ensembl ID : ENSMAMG00000021256
Gene Symbol: LOC113127497
2 Cross references
220 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSMAMG00000028476
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSMAMG00000007547
Gene Symbol: SLC18A2
2 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSMAMG00000018301
Gene Symbol: SLC22A6L
3 Cross references
358 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).